|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/517 | |
| A61P 35/00 |
| (11) | Patento numeris | 2303276 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09746098.4 |
| Europos patento paraiškos padavimo data | 2009-05-11 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-04-06 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-11-13 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2009/050496 |
| Data | 2009-05-11 |
| (87) | Numeris | WO 2009/138781 |
| Data | 2009-11-19 |
| (30) | Numeris | Data | Šalis |
| 52706 P | 2008-05-13 | US | |
| 110637 P | 2008-11-03 | US |
| (72) |
BOARDMAN, Kay, Alison, GB
HARD, Susan, Elizabeth, GB
DOBSON, Andrew, Hornby, GB
WHITLOCK, Brian, GB
|
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
| (54) | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE |
| FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE |